On the safety of nimesulide, a preferential COX-2 inhibitor

被引：0
作者：
Kulkarni, SK [1 ]
机构：
[1] Panjab Univ, Fac Pharmaceut Sci, Chandigarh 160014, India
来源：
CURRENT SCIENCE | 2002年 / 83卷 / 12期
关键词：
D O I：
暂无
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页码：1442 / 1443
页数：2
相关论文
共 11 条
[1]  
Bennett A, 2000, Expert Opin Pharmacother, V1, P277, DOI 10.1517/14656566.1.2.277
[2]  
Boelsterli UA, 2002, INT J CLIN PRACT, P30
[3]   Mechanisms of NSAID-induced hepatotoxicity - Focus on nimesulide [J].
Boelsterli, UA .
DRUG SAFETY, 2002, 25 (09) :633-648
[4]   In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: An overview [J].
Famaey, JP .
INFLAMMATION RESEARCH, 1997, 46 (11) :437-446
[5]  
GEORGE S, 1991, J CLIN GASTROENTEROL, V13, P205
[6]   DICLOFENAC-ASSOCIATED HEPATOTOXICITY [J].
HELFGOTT, SM ;
SANDBERGCOOK, J ;
ZAKIM, D ;
NESTLER, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (20) :2660-2662
[7]  
Kulkarni S. K., 1999, Indian Journal of Pharmacology, V31, P444
[8]  
Rabasseda X, 1996, DRUG TODAY, V32, P1
[9]   An analysis from clinico-epidemiological data of the principal adverse events from the COX-2 selective NSAID, nimesulide, with particular reference to hepatic injury [J].
Rainsford K.D. .
InflammoPharmacology, 1998, 6 (3) :203-221
[10]   Relationship of nimesulide safety to its pharmacokinetics: assessment of adverse reactions [J].
Rainsford, KD .
RHEUMATOLOGY, 1999, 38 :4-10
12